A prospective study on the cardio-metabolic effects of apremilast in patients with psoriatic arthritis

Completed

• Conditions: inflammatory arthritis; psoriatic arthritis; 10023213; 10003216

• Registration Number: NL-OMON43353
• Lead Sponsor: Reade

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

- Adult (>=18 years) patients with active psoriatic arthritis
- Starting apremilast

Exclusion Criteria

- Inability or unwillingness to sign informed consent
- Contraindication for apremilast (i.e. pregnancy and hypersensitivity to apremilast and/or its excipients)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Body composition assessed using whole body DEXA</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Medical history, date of birth, gender, ethnicity, smoking status, use of<br /><br>alcohol, physical activity, date of diagnosis, comorbidity, concomitant<br /><br>medication, use of concomitant and prior DMARDs, height, weight, blood<br /><br>pressure, heart rate, abdominal wall and hip circumference, presence of<br /><br>peripheral arthritis, patient pain VAS, patient global assessment of disease<br /><br>activity (VAS), PASI, LEI, RAPID, ESR, hsCRP, HbA1c (only in patients diagnosed<br /><br>with diabetes mellitus), TC, HDL, LDL, Apo, HDL efflux capacity, glucose, ICAM,<br /><br>VCAM, adiponectines, PCSK9, cIMT, DECT-scan</p><br>